ADAR1 Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

ADAR1 Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$465K	Hold	42,900	–	–	0.02%	217
2026 Q1	$477K	Hold	42,900	–	–	0.03%	207
2025 Q4	$712K	Hold	42,900	–	–	0.05%	164
2025 Q3	$505K	Sell	42,900 -20,524	-32%	-$212K	0.05%	135
2025 Q2	$608K	Buy	63,424 +20,624	+48%	+$114K	0.09%	107
2025 Q1	$268K	Sell	42,800 -12,600	-23%	-$76.5K	0.05%	132
2024 Q4	$450K	Buy	55,400 +55,200	+27,600%	+$684K	0.09%	116
2024 Q3	$3.62K	Buy	+200	New	+$2.79K	﹤0.01%	264

Other funds holding PHAT

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ADAR1 Capital Management's PHAT Position: Q2 2026 in Review

ADAR1 Capital Management held its Phathom Pharmaceuticals (PHAT) position steady in Q2 2026 at 42,900 shares worth $465K. The position accounts for 0.02% of the portfolio, ranked #217.

ADAR1 Capital Management first reported a position in PHAT in Q3 2024 and has held it in 8 quarters since. The position peaked at $712K in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

ADAR1 Capital Management held 42,900 shares of Phathom Pharmaceuticals worth $465K as of Q2 2026.
ADAR1 Capital Management left its Phathom Pharmaceuticals share count unchanged in Q2 2026.
Phathom Pharmaceuticals made up 0.02% of ADAR1 Capital Management's portfolio in Q2 2026, its #217 holding.
ADAR1 Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
ADAR1 Capital Management's Phathom Pharmaceuticals position peaked at $712K in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.